Effects of ketorolac tromethamine on hemostasis in volunteers
| Autor: | Mary J. Mackie, Kenneth A. Conrad, Paula V. Mayshar, Timothy C. Fagan |
|---|---|
| Rok vydání: | 1988 |
| Předmět: |
Adult
Ecchymosis Pain Placebo Injections Intramuscular Ketorolac Tromethamine Bleeding time medicine Humans Pyrroles Pharmacology (medical) Tolmetin Tromethamine Pharmacology Prothrombin time Hemostasis Aspirin medicine.diagnostic_test business.industry Anti-Inflammatory Agents Non-Steroidal Middle Aged Ketorolac Drug Combinations Anesthesia business medicine.drug Partial thromboplastin time |
| Zdroj: | Clinical Pharmacology and Therapeutics. 43:542-546 |
| ISSN: | 1532-6535 0009-9236 |
| DOI: | 10.1038/clpt.1988.70 |
| Popis: | Ketorolac tromethamine, an analgesic agent with prostaglandin synthetase–inhibiting activity, is more active than aspirin in vitro in inhibiting collagen– or arachidonic acid–induced platelet aggregation. In this randomized, double-blind study, 26 volunteers received ketorolac, 30 mg intramuscularly four times a day for 5 days, and placebo, two capsules orally four times a day for at the last 2 study days. The effects of this treatment were compared with those of intramuscular placebo and oral aspirin, two 325 mg capsules, given on the same schedule to eight volunteers. Aspirin at a mean serum concentration of 84 μg/ml did not affect prothrombin time, partial thromboplastin time, platelet count, or bleeding time. Ketorolac produced a modest prolongation of the bleeding time, from 4.9 ±1.1 minutes (mean ± SD) to 7.8 ± 4.0 minutes (p < 0.005). Ketorolac did not affect the prothrombin time or partial thromboplastin time but was associated with clinically insignificant change in the platelet count from 303 ± 57 × 103/m3 to 277 ± 56 × 103/mm3. Clinical Pharmacology and Therapeutics (1988) 43, 542–546; doi:10.1038/clpt.1988.70 |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text